

Crizanlizumab, L-Glutamine, and Voxelotor for Sickle Cell Disease: Effectiveness and Value

Revised Background and Scope
September 30, 2019

Background

Sickle cell disease (SCD) is a broad term referring to a group of inherited disorders carried by the beta (β) allele of the hemoglobin gene (Hb). It is characterized by abnormal hemoglobin polymerization during deoxygenation resulting in sickle-shaped erythrocytes (red blood cells [RBCs]). SCD includes the genotypes HbSS, as well as the compound heterozygous genotypes HbS β^0 thalassemia, HbSC, HbSD, HbS β^+ thalassemia.¹ The genotypes HbSS and HbS β^0 thalassemia have similar clinical characteristics and together are frequently referred to as sickle cell anemia. Conversely, the heterozygous state with one normal gene and one Hb S gene (HbAS) is the carrier state and is referred to as “sickle cell trait.” Sickle cell trait usually does not have clinical manifestations and confers protection against plasmodium falciparum malaria.²

Clinical manifestations of SCD derive from at least three different pathophysiologic mechanisms: the loss of deformability of the RBC leading to vascular obstruction and ischemia; a shortened lifespan of the RBC leading to both intravascular and extravascular hemolysis; a sticky RBC surface increasing adherence to the vascular endothelium which can result in vascular obstruction and can contribute to vascular proliferative lesions.³

Rates of SCD and sickle cell trait vary considerably by geography with the highest rates found in populations arising from areas where, historically, resistance to plasmodium falciparum malaria conferred a survival advantage.² These include equatorial Africa, Brazil, Saudi Arabia and central India. The incidence of SCD is estimated at 300,000 to 400,000 live births globally per year. In the United States (US), the current best prevalence estimate is approximately 100,000 individuals with SCD, although comprehensive surveillance and reporting is lacking and the true number of cases in the US is unknown.⁴

A marked decrease in mortality in infancy occurred in the US from 1979-2006, presumably due to the implementation of universal newborn screening, penicillin prophylaxis, and the use of conjugated pneumococcal vaccine.⁴ During that same time, peak mortality shifted from the middle third decade of life to the late fourth decade of life with the mean age of death being 39 years.⁵

Despite improved survival, life expectancy continues to be 20-30 years less than the US general population.⁴

Recurrent acute pain crises, or vaso-occlusive crises (VOCs), are considered among the most common manifestation of SCD. An understanding of the pathophysiology of VOCs continues to evolve with recent models focused on the complex cascade of inflammation, adherence of leukocytes, and blood flow obstruction. The management of acute pain crises is extremely important in patients with SCD yet is often misunderstood or inadequately addressed across all healthcare settings.¹

In addition to VOCs, patients over time experience significant acute and chronic morbidity. Acute complications include serious infections such as meningitis, osteomyelitis, and sepsis, and non-infectious complications such as stroke, renal necrosis, and priapism.⁶ Acute chest syndrome is a potentially life-threatening complication that can involve chest pain and shortness of breath among other symptoms; some episodes of acute chest syndrome are triggered by infection.⁷ Chronic complications can emerge across multiple organs and include neurocognitive impairment, chronic kidney injury, delayed puberty, avascular necrosis, retinopathy, pulmonary hypertension, skin ulcers, and chronic pain.⁶ Individuals with SCD face ongoing and evolving lifelong difficulties as a result of their disease. As their bodies grow, develop, and age, new problems can emerge while intermittent and persistent vaso-occlusion/ischemia produce an accumulation of injuries over time.² Resultant health care costs are high, with the total health system economic burden of SCD estimated at \$2.98 billion per year in the US with 57% due to inpatient costs, 38% due to outpatient costs, and 5% due to out-of-pocket costs.⁸

At this time, only two interventions are considered disease modifying: chronic transfusion with packed RBCs and hydroxyurea.¹ Chronic transfusion is generally used for primary or secondary stroke prevention; hydroxyurea is used to reduce the number of VOCs in those with frequent or severe crises, and in those with a history of acute chest syndrome or severe anemia.¹ L-glutamine supplementation can also decrease the frequency of VOCs.⁹ Acute VOCs may be managed with pain medications including opioids, and may require additional inpatient or outpatient treatments including hydration, transfusion, supplemental oxygen, and a variety of other treatments.¹

There is clearly a large unmet need for additional treatments for SCD. Crizanlizumab (Novartis AG), is a humanized monoclonal antibody that binds to P-selectin. It is currently being evaluated by the US Food and Drug Administration (FDA) as prophylactic treatment for VOCs, with an approval decision expected by January 2020.¹⁰ It is administered intravenously every four weeks. Voxelotor (Global Blood Therapeutics, Inc.) is an HbS polymerization inhibitor that reversibly binds to hemoglobin to stabilize the oxygenated hemoglobin state, thus shifting the oxyhemoglobin dissociation curve.¹¹ Voxelotor is currently being evaluated by the FDA as a treatment to increase Hb levels. It is administered orally and is dosed daily. A rolling New Drug Application requesting

accelerated approval for voxelotor has been accepted by the FDA with an anticipated decision by February 26, 2020.

Stakeholder Input

This draft scoping document was developed with input from diverse stakeholders, including patients and their families, clinicians, researchers, and manufacturers of the agents of focus in this review. This document incorporates feedback gathered during preliminary calls with stakeholders and open input submissions from the public. This final scoping document also reflects input from the public gathered during a three-week public comment period, during which we received input from 101 stakeholders, including 93 letters from patients, caregivers, and patient groups. ICER looks forward to continued engagement with stakeholders throughout its review and encourages comments to refine our understanding of the clinical effectiveness and value of preventive treatments.

We heard from patients and patient groups about the significant burden of SCD. Many patients had difficulty working or staying in school. Many lost jobs or dropped out of school because of frequent or prolonged absences due to acute SCD-related events. Family members described some of the burdens of caregiving, including the need to leave the work force to provide care. Both individuals and families reported significant financial hardship as a result of SCD. In addition to lost wages, patients and their families reported significant out-of-pocket costs due to the disease.

Some patients and family members described making decisions to avoid marriage to maintain health insurance or forego having children to avoid passing on the gene to the next generation. Families often had multiple members affected by SCD and described the emotional pain from watching parents, children, and siblings suffer and then die at an early age. A number of patients reported serious problems with mental health issues such as depression, anxiety, and suicidal thoughts.

We heard repeated concerns that there were not enough doctors and other medical providers adequately trained in the management of SCD. This resulted in patients either not having good access to local medical care or inconsistent care across various healthcare settings. We also heard that patients had often been perceived as drug-seeking resulting in important delays in getting adequate pain medication, and for some even life-saving interventions. This was further heightened by racism and bias against the populations of color most affected by SCD. Patients and family members were frustrated by the lack of good information or medical education on their disease. They expressed additional frustration by the lack of available therapies for their condition relative to other diseases. They were also concerned that even when new treatments become available, there will be delays in access due to lack of provider knowledge.

Everyone we spoke with expressed excitement at the possibility of new treatments for this severe disease.

Report Aim

This project will evaluate the health and economic outcomes of crizanlizumab, voxelotor, and prescription-grade formulations of L-glutamine for SCD. The ICER value framework includes both quantitative and qualitative comparisons across treatments to ensure that the full range of benefits and harms – including those not typically captured in the clinical evidence such as innovation, public health effects, reduction in disparities, and unmet medical needs – are considered in the judgments about the clinical and economic value of the interventions.

Scope of Clinical Evidence Review


The proposed scope for this assessment is described on the following pages using the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. Evidence will be abstracted from randomized controlled trials as well as high-quality systematic reviews; high-quality comparative cohort studies will also be considered, particularly for long-term outcomes and uncommon adverse events (AEs). Our evidence review will include input from patients and patient advocacy organizations, data from regulatory documents, information submitted by manufacturers, and other grey literature when the evidence meets ICER standards (for more information, see <https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/grey-literature-policy/>).

All relevant evidence will be synthesized qualitatively or quantitatively. Wherever possible, we will seek out head-to-head studies of the interventions and comparators of interest. Data permitting, we will also consider combined use of direct and indirect evidence in network meta-analyses of selected outcomes. Full details regarding the literature search, screening strategy, data extraction, and evidence synthesis will be provided after the finalized scope in a research protocol published on the Open Science Framework website (<https://osf.io/7awvd/>).

Analytic Framework

The general analytic framework for assessment of therapies for SCD is depicted in Figure 1 on the following page.

Figure 1. Analytic Framework: Crizanlizumab, L-Glutamine, and Voxelotor for SCD



AE: adverse event, SAE: serious adverse event, SCD: sickle cell disease, TEAE: treatment-emergent adverse events, VOCs: vaso-occlusive crises

The diagram begins with the population of interest on the left. Actions, such as treatment, are depicted with solid arrows which link the population to outcomes. For example, a treatment may be associated with specific health outcomes. Outcomes are listed in the shaded boxes; those within the rounded boxes are intermediate outcomes (e.g., laboratory measures), and those within the squared-off boxes are key measures of benefit (e.g., vaso-occlusive crises). The key measures of benefit are linked to intermediate outcomes via a dashed line, as the relationship between these two types of outcomes may not always be validated. An arrow from interventions lead to the AEs of treatment which are listed within the blue ellipse.

Populations

The population of focus for this review is children and adults two years of age and older diagnosed with SCD.

We will look for information on subgroups that may experience smaller or larger net benefits than the population as a whole. These include but are not limited to subgroups defined by:

- Age
- Hydroxyurea use
- Use of chronic transfusions
- Sickle cell genotype
- Frequency of VOCs
- Location of care
- Socioeconomic status

We recognize that some of these data may be limited, but based on patient input we wish to highlight that some of these subgroups reflect issues with differential cost effectiveness and other issues around generalizability from results of randomized trials to a real-world population.

Interventions

The interventions of interest for this review are listed below:

- Crizanlizumab (investigational; Novartis AG) in addition to usual care (e.g., hydroxyurea, transfusions)
- Voxelotor (investigational; Global Blood Therapeutics, Inc.) in addition to usual care (e.g., hydroxyurea, transfusions)
- Prescription-grade formulations of L-Glutamine (e.g., Endari™; Emmaus Medical, Inc.) in addition to usual care (e.g., hydroxyurea, transfusions)

Comparators

We intend to compare each intervention to usual care alone. We do not expect to compare the interventions to each other.

Outcomes

The key outcomes of interest are described in Table 1 below.

Table 1. Key Outcomes and Harms

Outcomes	Key Harms
Mortality	Serious adverse events (SAEs)
Acute pain crisis (i.e., vaso-occlusive crisis)	Treatment-emergent adverse events (TEAEs)
Hospitalization	AEs leading to discontinuation
Chronic pain	
Fatigue	
Cognitive effects	
Acute chest syndrome	
Mental health effects (e.g., depression, anxiety)	
Splenic sequestration	
Cardiovascular events (e.g., stroke and silent infarcts, pulmonary hypertension, heart failure)	
Hearing loss	
Vision loss	
Organ damage	
Pregnancy complications	
Quality of life	

Additional intermediate and surrogate outcomes of interest include:

- Hemoglobin levels
- Laboratory markers of hemolysis
- Need for blood transfusions

Timing

Evidence on intervention effectiveness and evidence on harms will be derived from studies of any duration.

Settings

All relevant settings will be considered, with a focus on outpatient settings in the US.

Potential Other Benefits and Contextual Considerations

Our reviews seek to provide information on potential other benefits offered by the interventions to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. These elements are listed in the table below.

Table 2. Potential Other Benefits and Contextual Considerations

Potential Other Benefits
This intervention offers reduced complexity that will significantly improve patient outcomes.
This intervention will reduce important health disparities across racial, ethnic, gender, socio-economic, or regional categories.
This intervention will significantly reduce caregiver or broader family burden.
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.
This intervention will have a significant impact on improving return to work and/or overall productivity.
Other important benefits or disadvantages that should have an important role in judgments of the value of this intervention.
Potential Other Contextual Considerations
This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
This intervention is the first to offer any improvement for patients with this condition.
Compared to “the comparator,” there is significant uncertainty about the long-term risk of serious side effects of this intervention.
Compared to “the comparator,” there is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
There are additional contextual considerations that should have an important role in judgments of the value of this intervention.

ICER encourages stakeholders to provide input on these elements in their public comment submissions.

Scope of Comparative Value Analyses

As a complement to the evidence review, we will develop a Markov cohort model to assess the lifetime cost-effectiveness of the treatments of interest relative to usual care without one of the new treatments. The model structure will be based in part on a literature review of prior published models of SCD treatments and/or screening.¹²⁻²⁰ The base-case analysis will take a health care system perspective (i.e., focus on direct medical care costs only). Indirect costs and effects (such as productivity loss) will be considered in a separate analysis using a societal perspective. The target population will consist of children and adults ages two and older with SCD. The model will include health states for SCD with and without VOC; as data permit, we will also model health states for the sequelae of major morbidities of SCD, including stroke, myocardial infarction, pulmonary disease, splenic sequestration, chronic infection, end-organ damage, chronic pain, and disutilities associated with these events, as well as other events such as hospitalizations and acute chest syndrome. A cohort of patients will transition between states during annual cycles over a lifetime time horizon

(using a 3% discount rate for costs and outcomes), modeling patients from treatment initiation until death.

Key model inputs will include clinical probabilities, quality of life values, and health care costs. Probabilities, costs, and other inputs will differ to reflect varying effectiveness between interventions. Treatment effectiveness will be estimated using clinical trial results for each treatment. As data permit, relevant subgroup analyses (e.g., by race/ethnicity, age, chronic transfusion) will be performed.

Health outcomes and costs will be dependent on time spent in each health state, clinical events, AEs, and direct medical costs. The health outcome of each intervention will be evaluated in terms of VOCs avoided, life-years, equal value life years gained (evLYG), and quality-adjusted life years (QALYs) gained. Quality of life weights will be applied to each health state, including quality of life decrements for SAEs. The model will include direct medical costs, including but not limited to costs related to drug administration, drug monitoring, condition-related care, and SAEs. In addition, productivity losses and other indirect costs will be included in a separate analysis using a modified societal perspective, as data allow. Expected costs and outcomes will be tabulated for each treatment and its comparator, and results will be expressed in terms of the marginal cost per QALY gained, cost per life-year gained, cost per evLYG, and cost per VOC avoided.

In separate analyses, we will explore the potential health system budgetary impact of treatment over a five-year time horizon, utilizing published or otherwise publicly available information on the potential population eligible for treatment and results from the simulation model for treatment costs and cost offsets. This budgetary impact analysis will indicate the relation between treatment prices and level of use for a given potential budget impact, and will allow assessment of any need for managing the cost of such interventions.

More information on ICER's methods for estimating potential budget impact can be found at: <http://icer-review.org/wp-content/uploads/2018/05/ICER-value-framework-v1-21-18.pdf>.

Identification of Low-Value Services

As described in its Final Value Assessment Framework for 2017-2019, ICER will now include in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create additional resources in health care budgets for higher-value innovative services (for more information, see <https://icer-review.org/material/final-vaf-2017-2019/>). These services are ones that would not be directly affected by crizanlizumab or voxelotor (e.g., reductions in VOCs), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of SCD beyond the potential offsets that arise from a new intervention. ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) that could be reduced, eliminated, or made more efficient.

References

1. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members Management of Sickle Cell Disease. *JAMA*. 2014;312(10):1033-1048.
2. Serjeant GR. The natural history of sickle cell disease. *Cold Spring Harb Perspect Med*. 2013;3(10):a011783-a011783.
3. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. *Blood*. 2016;127(7):810-819.
4. Hassell KL. Population Estimates of Sickle Cell Disease in the U.S. *American Journal of Preventive Medicine*. 2010;38(4, Supplement):S512-S521.
5. CDC NcfHS. Compressed mortality file 1999-2006. 2009; Wonder.cdc.gov/cmfc-icd10html.
6. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. *Nature Reviews Disease Primers*. 2018;4:18010.
7. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. *The New England journal of medicine*. 2000;342(25):1855-1865.
8. Huo J, Xiao H, Garg M, Shah C, Wilkie DJ, Mainous Iii A. The Economic Burden of Sickle Cell Disease in the United States. *Value in Health*. 2018;21:S108.
9. Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*. 2018;379(3):226-235.
10. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. *The New England journal of medicine*. 2017;376(5):429-439.
11. Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *The New England journal of medicine*. 2019;381(6):509-519.
12. Bryan S, Dormandy E, Roberts T, et al. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. *Br J Gen Pract*. 2011;61(591):e620-627.
13. Cherry MG GJ, Osipenko L, Vankatachalam M, Boalnd A, Dundar Y, Marsh K, Dickson R, Rees DC. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. *Health Technology Assessment*. 2012;16(43).
14. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. *Transfusion*. 2014;54(1):86-97.
15. Kacker S, Ness PM, Savage WJ, et al. Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. *Transfusion*. 2014;54(8):2034-2044.
16. Kuznik A, Habib AG, Munube D, Lamorde M. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. *BMC Health Serv Res*. 2016;16:304.
17. McGann PT, Grosse SD, Santos B, et al. A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola. *J Pediatr*. 2015;167(6):1314-1319.
18. Moore RD CS, Terrin ML, Barton FB, Ballas SK, Investigators fo the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. . Cost-effectiveness of hydroxyurea in sickle cell anemia. *American Journal of Hematol;ogy*. 2000;64:26-31.

19. Spackman E, Sculpher M, Howard J, et al. Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. *Eur J Haematol*. 2014;92(3):249-255.
20. Stallworth JR JJ, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. *American Journal of Hematology*. 2010:795-797.